Related Experiment Video

Updated: Feb 20, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K

Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms

Charlie George Barker1,2, Sumana Sharma1,3, Ana Mafalda Santos3

  • 1European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK.

Molecular Systems Biology
|February 18, 2026
PubMed

Insights

ARID1A loss in melanoma promotes resistance to BRAF/MAPK inhibitors by altering cell signaling and immune evasion pathways. Targeting PRKD1, JUN, and NCK1 may overcome this resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Systems Biology

Background:

  • BRAF/MAPK inhibitors are crucial for melanoma treatment but face resistance.
  • ARID1A mutations are common in melanoma and associated with resistance and immune evasion.
  • Understanding early signaling responses is key to overcoming therapeutic resistance.

Purpose of the Study:

  • To investigate the molecular mechanisms of BRAF/MAPK inhibitor resistance in ARID1A-knockout melanoma cells.
  • To identify key signaling nodes and pathways involved in therapeutic evasion.
  • To explore potential therapeutic targets for overcoming resistance.

Main Methods:

  • Comparative analysis of a BRAFV600E-sensitive melanoma cell line and its ARID1A-knockout derivative.
  • Integration of multi-omics datasets (transcriptomics, proteomics, etc.) using a systems biology approach.
  • Analysis of signaling pathway activation, receptor tyrosine kinase (RTK) activity, and immune-related gene expression.

Main Results:

  • ARID1A-knockout cells exhibit transcriptional rewiring, maintaining MAPK1/3 and JNK activity post-treatment.
  • Suppressed PRKD1 activation, increased JUN activity, and disrupted PKC dynamics were observed in ARID1A-KO cells.
  • Elevated RTK (EGFR, ROS1) and Ephrin receptor activity, reduced HLA-related protein expression, and enhanced extracellular matrix components were identified.
  • PRKD1, JUN, and NCK1 were identified as critical nodes driving resistance.

Conclusions:

  • ARID1A loss confers resistance to BRAF/MAPK inhibitors through complex signaling alterations.
  • ARID1A-knockout impacts immune evasion mechanisms, potentially affecting immunotherapy efficacy.
  • PRKD1, JUN, and NCK1 represent promising therapeutic targets to overcome melanoma treatment resistance.
Keywords:
ARID1AData IntegrationDrug ResistanceMelanomaNetwork Analysis

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K